Which companies overlap with National Research Center for Hematology, Russia's portfolio?

Top competitors by shared drug class: AbbVie, Asan Medical Center, AstraZeneca, Avicenna Research Institute, Biosolution Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/national-research-center-for-hematology-russia.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

National Research Center for Hematology, Russia — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

National Research Center for Hematology, Russia pipeline: 2 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 4 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
standard dose ARA-C	standard dose ARA-C	marketed	Nucleoside analog antimetabolite	DNA polymerase; ribonucleotide reductase	Oncology
Mesenchymal stromal cells	Mesenchymal stromal cells	marketed	Cell therapy		Immunology, Regenerative Medicine
R-mNHL-BFM-90	R-mNHL-BFM-90	phase 3	Chemotherapy regimen		Oncology
R-DA-EPOCH-21 + auto-SCT	R-DA-EPOCH-21 + auto-SCT	phase 3	Chemotherapy regimen	CD20 (rituximab)	Oncology
R-DA-EPOCH-21	R-DA-EPOCH-21	phase 3	chemotherapy regimen		Oncology
R-mNHL-BFM-90 + auto-SCT	R-mNHL-BFM-90 + auto-SCT	phase 3	Rituximab-based chemotherapy regimen with autologous stem cell transplantation	CD20	Oncology

Therapeutic area mix

Oncology · 5
Immunology, Regenerative Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AbbVie · 1 shared drug class
Asan Medical Center · 1 shared drug class
AstraZeneca · 1 shared drug class
Avicenna Research Institute · 1 shared drug class
Biosolution Co., Ltd. · 1 shared drug class
Bone Therapeutics S.A · 1 shared drug class
Brainstorm-Cell Therapeutics · 1 shared drug class
AIO-Studien-gGmbH · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for National Research Center for Hematology, Russia:

Cite this brief

Drug Landscape (2026). National Research Center for Hematology, Russia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/national-research-center-for-hematology-russia. Accessed 2026-05-17.